Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-04-23-Speech-1-108"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2007-04-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Advanced therapy medicinal products (debate)2
dcterms:Language	"el"^^xsd:language2
lpv:document identification number	"en.20070423.17.1-108"2
lpv:hasSubsequent	lp_eu:2007-04-23-Speech-1-1092
lpv:speaker	lp:Adamos Adamou2
lpv:spokenAs	unknown; Anorthotiko Komma Ergazomenou Laou - Aristera - Nees Dynameis (2004-07-20--2009-07-13)3 member; Delegation for relations with Australia and New Zealand (2007-03-15--2009-07-13)3 member; Delegation to the Euro-Mediterranean Parliamentary Assembly (2007-03-15--2009-07-13)3 substitute; LIBE (2007-01-31--2009-07-13)3 member; EUL/NGL (2004-07-20--2009-07-13)3 substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (2007-03-15--2009-07-13)3 member; ENVI (2007-01-31--2009-07-13)3 substitute; Delegation to the EU-Chile Joint Parliamentary Committee (2004-09-15--2009-07-13)3
lpv:translated text	"Mr President, Commissioner, I too should like to take my turn in emphasising that the purpose of this proposal is not to harmonise questions of ethics or morals; it is for the national competence of the Member States to be respected as regards whether or not sensitive products are used. Such decisions must be taken on the basis of the principle of subsidiarity and must remain within the national competence of each Member State. The personal, moral and ethical views of each of us must not conflict with this approach, especially as each Member State will be responsible for deciding which type of products it will allow to be imported and which not. The crucial question is whether or not we agree that Europe should decide which products we shall market and which we must ban. My answer is no. Let me now remind you of the package of amendments – Amendments 82 to 156 – which also reflects the six months of consultations and attempts to reach a compromise with the Council and the European Commission. Our objective is to reach a compromise at first reading, which is what is wanted by most of the associations of patients whose lives, in many cases, depend on a leading edge medicinal product. In short, the immediate application of the regulation would mean easier, faster and safer therapies for European patients. Europe needs this regulation and it needs it now."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph